Adrianna Brzozowska

Prof. Adrianna Brzozowska


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2025 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
HBHubert Bochenek
Hubert Bochenek
ABAnna Bielicka
Anna Bielicka
MBMichał Bzoma
Michał Bzoma
JGJulia Gugulska
Julia Gugulska
ICIrmina Czerepak
Irmina Czerepak
Adrianna BrzozowskaAdrianna Brzozowska
Adrianna Brzozowska
Introduction and purpose: aa Chronic coronary artery disease (CAD) is a prevalent condition affecting millions of people worldwide, significantly reducing quality of life and increasing the risk of myocardial infarction (MI). Percutaneous coronary intervention (PCI), often combined with stent implantation, is a cornerstone of CAD treatment. However, it induces a prothrombotic state, necessitating dual antiplatelet therapy (DAPT) to mitigate the risk of thrombosis and MI. Despite its established role, the optimal duration and specific composition of DAPT still remain under investigation. This article aims to summarise current knowledge on DAPT and highlight gaps requiring further research. Description of the state of knowledge: DAPT typically involves acetylsalicylic acid (ASA) 75 mg and clopidogrel 75 mg for 6 months after PCI. While this is effective in reducing thrombotic events, it also increases bleeding risk. Current European Society of Cardiology (ESC) guidelines recommend tailoring DAPT duration and composition based on individual patient risk factors for bleeding and ischemia. Alternatives include shortening DAPT to 1–3 months for patients with high bleeding risk or intensifying it with stronger antiplatelet agents like ticagrelor or prasugrel for those at high ischemic risk. However, evidence supporting these alternatives remains limited, and require further investigation. Emerging options, such as vorapaxar, present additional potential, but also require further validation. Summary: CAD management through PCI relies heavily on effective DAPT. Current strategies emphasize balancing ischemic and bleeding risks in optimising treatment. Although significant progress has been made, optimal DAPT regimens for specific patient groups remain uncertain, particularly in cases of shortened or intensified therapy. Continued research is crucial to refine treatment protocols and improve patient outcomes.

13 June 2025 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
ICIrmina Czerepak
Irmina Czerepak
MKMarcin Kapij
Marcin Kapij
HBHubert Bochenek
Hubert Bochenek
MBMichał Bzoma
Michał Bzoma
JGJulia Gugulska
Julia Gugulska
Adrianna BrzozowskaAdrianna Brzozowska
Adrianna Brzozowska
Introduction and purpose: Postpartum depression (PPD) is a prevalent and serious mood disorder following childbirth, affecting approximately 10-20% of new mothers worldwide. PPD not only impacts a mother’s mental health but also her relationship with her infant, her family, and the psychosocial development of the child. While numerous factors (genetic, hormonal, psychosocial, immunological) contribute to its pathogenesis, growing evidence underscores the central importance of the gut-brain axis and gut microbiota dysbiosis. This article aims to summarise current knowledge on crucial role of gut microbiota in the onset, progression and therapeutic possibilities of PPD.Description of the state of knowledge: Gut microbes influence PPD through the gut-brain axis, impacting neuroendocrine systems, immune responses, and neurotransmitter production. In particular, alterations in gut microbiota composition such as reduced levels of short-chain fatty acid-producing bacteria and an increased abundance of pro-inflammatory taxa have been linked to immune dysregulation, heightened stress responses, and altered neurotransmitter metabolism in PPD. Studies show that microbial dysbiosis correlate with PPD symptoms, while interventions like probiotics and dietary changes offer promising therapeutic avenues.Summary: This review summarizes current evidence on the gut–brain axis in depression, observed gut microbiota changes in PPD, mechanistic pathways linking dysbiosis to postpartum mood disturbances, and emerging microbiota-targeted therapies, including probiotics and fecal microbiota transplantation (FMT).

22 July 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MBMichał Bzoma
Michał Bzoma
HBHubert Bochenek
Hubert Bochenek
PKPaweł Kamiński
Paweł Kamiński
ICIrmina Czerepak
Irmina Czerepak
JGJulia Gugulska
Julia Gugulska
Adrianna BrzozowskaAdrianna Brzozowska
Adrianna Brzozowska
Introduction and Purpose: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), represents the most common chronic liver condition worldwide, strongly linked to obesity and type 2 diabetes. The more severe form, metabolic dysfunction-associated steatohepatitis (MASH), significantly increases risks of cirrhosis, hepatocellular carcinoma, and cardiovascular complications. Currently, effective pharmacological treatments are limited. This review aims to summarize current evidence on the potential role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as therapeutic agents for MASLD/MASH. Description of the State of Knowledge: GLP-1 RAs, currently used to treat diabetes and obesity, show beneficial metabolic effects through appetite reduction, weight loss, and improved glycemic control. Recent studies indicate that GLP-1 RAs, particularly liraglutide and semaglutide, effectively reduce liver steatosis, hepatic inflammation, and liver enzymes. However, evidence regarding their effectiveness in reducing liver fibrosis remains unclear, highlighting the need for larger and longer studies. Conclusions: GLP-1 RAs emerge as promising therapeutic options for MASLD and MASH due to their metabolic and hepatoprotective benefits. While preliminary findings support their use, particularly in reducing hepatic steatosis and inflammation, their role in fibrosis regression requires further validation. Future research, involving extensive clinical trials with broader patient populations and standardized dosing protocols, is essential to establish GLP-1 RAs as standard therapy for metabolic liver disease.

16 July 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
KKKatarzyna Kozon
Katarzyna Kozon
KKKatarzyna Krupa
Katarzyna Krupa
PFPatrycja Fiertek
Patrycja Fiertek
Adrianna BrzozowskaAdrianna Brzozowska
Adrianna Brzozowska
KNKarolina Niewczas
Karolina Niewczas
MSMarcin Sawczuk
Marcin Sawczuk
Dravet syndrome is a severe, early childhood epileptic encephalopathy, most often associated with a mutation in the SCN1a gene characterized by drug resistance and high neurological burden. For many years treatment was limited to non-specific antiepileptic drugs, but recently new, targeted therapies have appeared, which have significantly improved the prognosis of patients. Stiripentol, modulating GABAergic transmission, has been approved as an adjuctive treatment in the treatment of Dravet syndrome, showing a significant reduction in the frequency of seizures in combination with clobazam and valproic acid. In turn, fenfluramine, acting on serotonin receptors, among others, has proven also effective. Both drugs have been approved by the FDA and EMA, constitiuting a breakthrough in the treatment of Dravet syndrome Their introduction has significantly improved the quality of life of patients and opened up new perspectives in the treatment of developmental epilepsies.

27 June 2025 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
KNKarolina Niewczas
Karolina Niewczas
Adrianna BrzozowskaAdrianna Brzozowska
Adrianna Brzozowska
MBMichał Bzoma
Michał Bzoma
JGJulia Gugulska
Julia Gugulska
ABAnna Bielicka
Anna Bielicka
HBHubert Bochenek
Hubert Bochenek
Introduction and purpose: Osteoporosis is a common cause of proximal femoral fractures, which also are called hip fractures. The incidence of osteoporosis is increasing and becoming widely population disease. The division of proximal femoral fractures is based on anatomy, which includes trochanter, neck and head of femur fractures. There are the most severe osteoporotic fractures with a high mortality and disability. Therefore, decreased thickness in osteoporosis implies mechanical difficulties with treatment. Treatment is dependent on the appropriate scales, related to the anatomical division of hip fractures. It contains appropriate fixation with sliding hip screw with plate or nailing. In other cases, especially in elderly patients with symptomatic hip arthritis, total hip arthroplasty may be considered. Aim of the study: Proximal femoral fractures in osteoporotic patients are not only associated with difficulties in treatment, but more importantly with high mortality and disability. This is why further development of treatments is so important. In the following work, it is shown up-to-date methods of treatment proximal femoral fractures. Furthermore, promising method with enhanced screw fixation with augmentation is shown with particular attention to safety and good functional results. Material and methods: Review of studies available through sources on PubMed, Google Scholar, and the National Library of Medicine. Conclusions: Proximal femoral fractures vary significantly in treatment depending on the division by anatomy. In addition to anatomy, it is important to consider age and co-morbid symptomatic hip arthritis in treatment. The cement augmentation of the proximal femoral nail antirotation increases the implant stability in osteoporotic proximal femoral fractures. Moreover, cement augmentation is safe method of treatment with good fracture healing.

13 August 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
BPBarbara Pękowska
Barbara Pękowska
Adrianna BrzozowskaAdrianna Brzozowska
Adrianna Brzozowska
KNKarolina Niewczas
Karolina Niewczas
KKKatarzyna Kozon
Katarzyna Kozon
ABAnna Bielicka
Anna Bielicka
DDDominik Domoń
Dominik Domoń
Objective: Allergic diseases, including asthma, atopic dermatitis (AD) and allergic rhinitis (AR), are increasingly prevalent and significantly impact quality of life. These conditions are driven by an overactive Th2 immune response, leading to chronic inflammation. There is growing interest in novel therapies, such as quercetin, Lactobacillus species and vitamin D₃, which exhibit immunomodulatory properties and could offer new therapeutic strategies for managing allergic diseases. Methods: This review explores the role of quercetin, Lactobacillus spp. and vitamin D₃ in modulating immune responses associated with asthma, atopic dermatitis and allergic rhinitis. We examined current literature on their mechanisms of action, effects on immune modulation and clinical evidence supporting their use in allergic conditions. Key findings: Quercetin demonstrated anti-inflammatory, antioxidant, and immunomodulatory effects, reducing Th2 cytokine production and mitigating inflammation in asthma, atopic dermatitis and allergic rhinitis. Lactobacillus species, especially L. rhamnosus and L. plantarum, promoted immune tolerance by enhancing regulatory T cell activity and improving gut barrier integrity. Vitamin D₃, through its active form calcitriol, attenuated Th2-driven inflammation, strengthened epithelial barriers, and improved clinical outcomes in asthma, atopic dermatitis and allergic rhinitis. Conclusions: Quercetin, Lactobacillus spp. and vitamin D₃ show promising potential as adjunctive therapies in allergic diseases. These interventions modulate key immune pathways, reduce inflammation and restore immune balance. However, further research is needed to establish optimal dosages and treatment regimens.